Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer

Oncotarget

Volumn 5, Issue 3, 2014, Pages 764-774

  Crea, Francesco ^a   Watahiki, Akira ^a,b   Quagliata, Luca ^c   Xue, Hui ^a   Pikor, Larissa ^a   Parolia, Abhijit ^a,d   Wang, Yuwei ^a   Lin, Dong ^a,b   Lam, Wan L ^a   Farrar, William L ^e   Isogai, Takao ^f   Morant, Rudolf ^g   Castori Eppenberger, Serenella ^c   Chi, Kim N ^b,h   Wang, Yuzhuo ^a,b   Helgason, Cheryl D ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e DoCoMo USA Laboratories   (United States)

^f FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^g Tumor Center ZeTuP   (Switzerland)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Androgen receptor; Cancer biomarkers; Long non coding rna; Metastasis; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CASPASE 3; CASPASE 7; LONG UNTRANSLATED RNA; PCAT18 PROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE; HUMAN; HUMAN TISSUE; LOC728606 GENE; MALE; METASTASIS; METASTATIC PROSTATE CANCER; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE HYPERTROPHY; RNA SEQUENCE; TRANSCRIPTOMICS; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; CELL GROWTH; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HETEROGRAFTS; HUMANS; MALE; MICE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; RNA, LONG NONCODING; TUMOR MARKERS, BIOLOGICAL;

EID: 84896847392     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1769     Document Type: Article

References (40)

1. Bishr M and Saad F. Overview of the latest treatments for castration-resistant prostate cancer. Nat Rev Urol. 2013.
2. Rodrigues G, Warde P, Pickles T, Crook J, Brundage M, Souhami L, Lukka H and Genitourinary Radiation Oncologists of C. Pre-treatment risk stratification of prostate cancer patients: A critical review. Canadian Urological Association journal = Journal de l'Association des urologues du Canada. 2012; 6(2):121-127.
3. Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT, Stadler PF, Hertel J, Hackermuller J, Hofacker IL, Bell I, Cheung E, Drenkow J, Dumais E, Patel S, Helt G, et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science. 2007; 316(5830):1484-1488.
4. Watahiki A, Macfarlane RJ, Gleave ME, Crea F, Wang Y, Helgason CD and Chi KN. Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer. International journal of molecular sciences. 2013; 14(4):7757-7770.
5. Chen G, Wang Z, Wang D, Qiu C, Liu M, Chen X, Zhang Q, Yan G and Cui Q. LncRNADisease: a database for long-non-coding RNA-associated diseases. Nucleic acids research. 2013; 41(Database issue):D983-986.
6. Gibb EA, Brown CJ and Lam WL. The functional role of long non-coding RNA in human carcinomas. Molecular cancer. 2011; 10:38.
7. Crea F, Clermont PL, Parolia A, Wang Y and Helgason CD. The non-coding transcriptome as a dynamic regulator of cancer metastasis. Cancer metastasis reviews. 2013.
8. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N and Isaacs WB. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer research. 1999; 59(23):5975-5979.
9. Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, Davis L, Livezey JR, Connell T, Sesterhenn IA, Yoshino K, Buzard GS, Mostofi FK, McLeod DG, Moul JW and Srivastava S. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(22):12216-12221.
10. Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA and Schalken JA. Prospective Multicentre Evaluation of PCA3 and TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary Biomarkers for Prostate Cancer. European urology. 2012.
11. Ferreira LB, Palumbo A, de Mello KD, Sternberg C, Caetano MS, de Oliveira FL, Neves AF, Nasciutti LE, Goulart LR and Gimba ER. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC cancer. 2012; 12:507.
12. Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L, Sesterhenn IA, Srikantan V, Moul JW and Srivastava S. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene. 2004; 23(2):605-611.
13. Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, Merkurjev D, Ohgi KA, Meng D, Zhang J, Evans CP and Rosenfeld MG. lncRNA-dependent mechanisms of androgenreceptor-regulated gene activation programs. Nature. 2013; 500(7464):598-602.
14. Luo M, Li Z, Wang W, Zeng Y, Liu Z and Qiu J. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer letters. 2013.
15. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ and Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010; 465(7301):1033-1038.
16. Fickett JW. Recognition of protein coding regions in DNA sequences. Nucleic acids research. 1982; 10(17):5303-5318.
17. Shtatland T, Guettler D, Kossodo M, Pivovarov M and Weissleder R. PepBank-a database of peptides based on sequence text mining and public peptide data sources. BMC bioinformatics. 2007; 8:280.
18. Michelhaugh SK, Lipovich L, Blythe J, Jia H, Kapatos G and Bannon MJ. Mining Affymetrix microarray data for long non-coding RNAs: altered expression in the nucleus accumbens of heroin abusers. Journal of neurochemistry. 2011; 116(3):459-466.
19. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S, Ghosh D and Chinnaiyan AM. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007; 9(2):166-180.
20. Wheeler DL, Church DM, Federhen S, Lash AE, Madden TL, Pontius JU, Schuler GD, Schriml LM, Sequeira E, Tatusova TA and Wagner L. Database resources of the National Center for Biotechnology. Nucleic acids research. 2003; 31(1):28-33.
21. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery. 2012; 2(5):401-404.
22. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, et al. Integrative genomic profiling of human prostate cancer. Cancer cell. 2010; 18(1):11-22.
23. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA and Murphy GP. LNCaP model of human prostatic carcinoma. Cancer research. 1983; 43(4):1809-1818.
24. Decker KF, Zheng D, He Y, Bowman T, Edwards JR and Jia L. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic acids research. 2012; 40(21):10765-10779.
25. Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, Wu R, Brahmbhatt S, Mo F, Jong L, Bell RH, Anderson S, Hurtado-Cull A, Fazli L, Sharma M, Beltran H, et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer research. 2013.
26. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S and Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. International journal of cancer Journal international du cancer. 1994; 57(3):406-412.
27. Miyagawa R, Tano K, Mizuno R, Nakamura Y, Ijiri K, Rakwal R, Shibato J, Masuo Y, Mayeda A, Hirose T and Akimitsu N. Identification of cis-and trans-acting factors involved in the localization of MALAT-1 noncoding RNA to nuclear speckles. Rna. 2012; 18(4):738-751.
28. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S and Rossi JJ. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nature biotechnology. 2005; 23(2):222-226.
29. Lin D, Bayani J, Wang Y, Sadar MD, Yoshimoto M, Gout PW and Squire JA. Development of metastatic and nonmetastatic tumor lines from a patient's prostate cancer specimen-identification of a small subpopulation with metastatic potential in the primary tumor. The Prostate. 2010; 70(15):1636-1644.
30. Watahiki A, Wang Y, Morris J, Dennis K, O'Dwyer HM, Gleave M, Gout PW and Wang Y. MicroRNAs associated with metastatic prostate cancer. PloS one. 2011; 6(9):e24950.
31. Lin D, Watahiki A, Bayani J, Zhang F, Liu L, Ling V, Sadar MD, English J, Fazli L, So A, Gout PW, Gleave M, Squire JA and Wang YZ. ASAP1, a gene at 8q24, is associated with prostate cancer metastasis. Cancer research. 2008; 68(11):4352-4359.
32. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, et al. Complete sequencing and characterization of 21,243 full-length human cDNAs. Nature genetics. 2004; 36(1):40-45.
33. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso CS, Kominsky HD, Cao X, Jing X, Wang X, Siddiqui J, Wei JT, Robinson D, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nature biotechnology. 2011; 29(8):742-749.
34. Ren S, Peng Z, Mao JH, Yu Y, Yin C, Gao X, Cui Z, Zhang J, Yi K, Xu W, Chen C, Wang F, Guo X, Lu J, Yang J, Wei M, et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancerassociated long noncoding RNAs and aberrant alternative splicings. Cell research. 2012; 22(5):806-821.
35. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, Chinnaiyan AM, Pienta KJ and Brown M. A hierarchical network of transcription factors governs androgen receptordependent prostate cancer growth. Molecular cell. 2007; 27(3):380-392.
36. Sharifi N. Minireview: Androgen metabolism in castrationresistant prostate cancer. Mol Endocrinol. 2013; 27(5):708-714.
37. Taylor RC, Cullen SP and Martin SJ. Apoptosis: controlled demolition at the cellular level. Nature reviews Molecular cell biology. 2008; 9(3):231-241.
38. Mortazavi A, Williams BA, McCue K, Schaeffer L and Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nature methods. 2008; 5(7):621-628.
39. Crea F, Duhagon Serrat MA, Hurt EM, Thomas SB, Danesi R and Farrar WL. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer. International journal of cancer Journal international du cancer. 2011; 128(8):1946-1954.
40. Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, Marquez VE, Danesi R and Farrar WL. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Molecular cancer. 2011; 10:40.